Huang C, Bei L, Liu T
2nd Municipal Hospital of Shan Tou, Shan Tou 515011.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1998 Aug;20(4):285-8.
CA50 and CA242 are newly recognized serum tumor marker. This study is to show their value in the diagnosis of digestive tract tumor.
164 patients with malignant digestive disease and 69 patients with benign disease were chosen. CA50 and CA242 level of these patients were measured by immunoradiometric assay.
The total sensitivity of CA50 and CA242 are 70% and 63% respectively. Two tumor markers rarely elevated in the patients with benign disease (false positive rate CA50 7.3%, CA242 4.3%). High percentage of elevated CA242 level was recorded in the patients with pancreatic and biliary cancers (Sensitivity 79%). Both have low sensitivity in patients with liver carcinoma.
CA50 and CA242 are valuable marker in the diagnosis of digestive tract tumor.
CA50和CA242是新发现的血清肿瘤标志物。本研究旨在展示它们在消化道肿瘤诊断中的价值。
选取164例恶性消化系统疾病患者和69例良性疾病患者。采用免疫放射分析法检测这些患者的CA50和CA242水平。
CA50和CA242的总灵敏度分别为70%和63%。两种肿瘤标志物在良性疾病患者中很少升高（CA50假阳性率7.3%，CA242假阳性率4.3%）。胰腺癌和胆管癌患者中CA242水平升高的比例较高（灵敏度79%）。两者对肝癌患者的灵敏度均较低。
CA50和CA242是消化道肿瘤诊断中有价值的标志物。
